Quarterly Financial Results for Q2 2026: This 10-Q filing covers Shoulder Innovations, Inc.'s financial performance for the six-month period ending June 30, 2026, and the specific quarter ending June 30, 2026 (Q2 2026) Company Overview: Shoulder Innovations, Inc. is a Delaware-incorporated medical device company in the surgical and medical instruments industry (SIC 3841), headquartered in Grand…

Our analysis rates this filing BEARISH. The HIGH concern level (7.6/10) reflects a company in early-stage transition with compounding risk factors. The combination of significant quantified equity dilution (0.0524 conversion ratio), recent IPO status with typical post-IPO volatility exposure,…

Concern level: HIGH (7.6/10). Key factors: Five new high-severity risks identified with average severity 7.2/10, including two risks rated 8/10 (Stock Split Conversion/Equity Dilution and Limited Operating History); Overall risk trend INCREASING with risk score of 7.8/10, indicating deteriorating risk profile; Significant equity dilution event quantified: Series E Second Tranche conversion ratio…

Notable risk changes: Company completed IPO on August 1, 2025 - transitioned from private to public company with associated regulatory and disclosure obligations. Early-stage public company status creates volatility and lockup expiration risks.; Series E Second Tranche conversion rights with 0.0524 ratio formalized - quantifies significant shareholder dilution event. Multiple conversion mechanisms (warrants,…

The model predicts SI will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.